Tourette Syndrome - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 77 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Tourette Syndrome - Pipeline Review, H1 2016

Summary


Global Markets Direct's, 'Tourette Syndrome - Pipeline Review, H1 2016', provides an overview of the Tourette Syndrome pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Tourette Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Tourette Syndrome
- The report reviews pipeline therapeutics for Tourette Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Tourette Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Tourette Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Tourette Syndrome

Reasons to buy


- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Tourette Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tourette Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Tourette Syndrome Overview 7
Therapeutics Development 8
Pipeline Products for Tourette Syndrome - Overview 8
Tourette Syndrome - Therapeutics under Development by Companies 9
Tourette Syndrome - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Tourette Syndrome - Products under Development by Companies 13
Tourette Syndrome - Companies Involved in Therapeutics Development 14
Catalyst Pharmaceutical Partners, Inc. 14
Edison Pharmaceuticals, Inc. 15
Neurocrine Biosciences, Inc. 16
Psyadon Pharmaceuticals, Inc. 17
Reviva Pharmaceuticals Inc. 18
Synchroneuron Inc. 19
Teva Pharmaceutical Industries Limited 20
Therapix Biosciences Ltd 21
Tourette Syndrome - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 31
acamprosate calcium SR - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CPP-115 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
deutetrabenazine ER - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
dronabinol + palmidrol - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ecopipam hydrochloride - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
RP-5063 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
valbenazine tosylate - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
vatiquinone - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
vigabatrin - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Tourette Syndrome - Recent Pipeline Updates 49
Tourette Syndrome - Dormant Projects 67
Tourette Syndrome - Discontinued Products 68
Tourette Syndrome - Product Development Milestones 69
Featured News & Press Releases 69
Feb 03, 2016: Psyadon Announces Positive Independent Review of Phase 2b Study of Ecopipam for the Treatment of Tourette's Syndrome in Children 69
Feb 02, 2016: Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome 69
Dec 16, 2015: Catalyst Pharmaceuticals Announces Top-Line Results in Phase 1(b) Trial of CPP-115 70
Dec 16, 2015: Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children with Tourette Syndrome 71
Oct 20, 2015: Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor NBI-98854 in Adults with Tourette Syndrome 71
Jan 14, 2015: Auspex Pharmaceuticals Receives FDA Orphan Drug Designation of SD-809 for Treatment of Tourette Syndrome in the Pediatric Population 72
Nov 24, 2014: Catalyst Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application for the Reduction or Elimination of Visual Field Defects by Treating Patients With CPP-115 72
Oct 02, 2014: Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study 73
May 28, 2014: Psyadon Announces the Opening of a New Clinical Trial of Ecopipam for the Treatment of Tourette's Syndrome in Children Ages 7-17 74
Jul 24, 2012: Psyadon Announces Positive Interim Analysis Of Phase II Study Of Ecopipam For Treatment Of Tourette Syndrome 74
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 76
Disclaimer 77

List of Tables

Number of Products under Development for Tourette Syndrome, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Comparative Analysis by Unknown Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Tourette Syndrome - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2016 14
Tourette Syndrome - Pipeline by Edison Pharmaceuticals, Inc., H1 2016 15
Tourette Syndrome - Pipeline by Neurocrine Biosciences, Inc., H1 2016 16
Tourette Syndrome - Pipeline by Psyadon Pharmaceuticals, Inc., H1 2016 17
Tourette Syndrome - Pipeline by Reviva Pharmaceuticals Inc., H1 2016 18
Tourette Syndrome - Pipeline by Synchroneuron Inc., H1 2016 19
Tourette Syndrome - Pipeline by Teva Pharmaceutical Industries Limited, H1 2016 20
Tourette Syndrome - Pipeline by Therapix Biosciences Ltd, H1 2016 21
Assessment by Monotherapy Products, H1 2016 22
Assessment by Combination Products, H1 2016 23
Number of Products by Stage and Target, H1 2016 25
Number of Products by Stage and Mechanism of Action, H1 2016 27
Number of Products by Stage and Route of Administration, H1 2016 29
Number of Products by Stage and Molecule Type, H1 2016 30
Tourette Syndrome Therapeutics - Recent Pipeline Updates, H1 2016 49
Tourette Syndrome - Dormant Projects, H1 2016 67
Tourette Syndrome - Discontinued Products, H1 2016 68